{"protocolSection": {"identificationModule": {"nctId": "NCT04147728", "orgStudyIdInfo": {"id": "Rvision-001"}, "organization": {"fullName": "Peking University Third Hospital", "class": "OTHER"}, "briefTitle": "Stereotactic Radiosurgery Combination With Anlotinib for Limited Brain Metastases With Perilesional Edema in NSCLC", "officialTitle": "Stereotactic Radiosurgery Combination With Anlotinib for Limited Brain Metastases With Perilesional Edema in Non-small Cell Lung Cancer：An Exploratory Single-Arm Phase II Clinical Trail", "acronym": "Rvision-001"}, "statusModule": {"statusVerifiedDate": "2019-10", "overallStatus": "UNKNOWN", "lastKnownStatus": "RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2019-12-24", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2021-12-15", "type": "ESTIMATED"}, "completionDateStruct": {"date": "2022-12-15", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2019-10-30", "studyFirstSubmitQcDate": "2019-10-31", "studyFirstPostDateStruct": {"date": "2019-11-01", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2020-03-01", "lastUpdatePostDateStruct": {"date": "2020-03-04", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Peking University Third Hospital", "class": "OTHER"}, "collaborators": [{"name": "Huashan Hospital", "class": "OTHER"}, {"name": "Tianjin Medical University", "class": "OTHER"}]}, "oversightModule": {"oversightHasDmc": true, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "The purpose of this study is to determine whether stereotactic radiosurgery combination with Anlotinib is safe, effective in the treatment of limited brain metastases with Perilesional edema in non-small cell lung cancer.", "detailedDescription": "The purpose of this study is to determine whether stereotactic radiosurgery combination with Anlotinib is safe, effective in the treatment of limited brain metastases with perilesional edema in non-small cell lung cancer. The sample size is 50. Patients start to take Anlotinib 1 week before the MRI-based simulation，12mg/d QD，day1\\~14, day22\\~36.Edema index will be used to evaluate the effectiveness of Anlotinib. The \"Edema index (EI)\" is calculated per the equation of \"edema index= (peri-tumoral edema volume+ tumor volume)/tumor volume."}, "conditionsModule": {"conditions": ["Stereotactic Body Radiation Therapy"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "NA", "interventionModel": "SINGLE_GROUP", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 50, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "SRS Combination With Anlotinib", "type": "EXPERIMENTAL", "description": "Stereotactic Radiosurgery Combination With Anlotinib", "interventionNames": ["Drug: Anlotinib", "Radiation: Stereotactic Radiosurgery"]}], "interventions": [{"type": "DRUG", "name": "Anlotinib", "description": "Anlotinib is a novel multi-target tyrosine Kinase inhibitor that inhibits VEGFR2/3, FGFR1-4, PDGFD α/β, c-Kit and Ret.", "armGroupLabels": ["SRS Combination With Anlotinib"], "otherNames": ["Antiangiogenic agents"]}, {"type": "RADIATION", "name": "Stereotactic Radiosurgery", "description": "Stereotactic Radiosurgery as the initial treatment of non small cell lung cancer patients with limited brain metastases", "armGroupLabels": ["SRS Combination With Anlotinib"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "EI", "description": "Edema Index. The \"Edema index (EI)\" is calculated per the equation of \"edema index= (peri-tumoral edema volume+ tumor volume)/tumor volume.", "timeFrame": "1 month"}], "secondaryOutcomes": [{"measure": "PFS", "description": "Progression-free Survival", "timeFrame": "1 year"}, {"measure": "OS", "description": "Overall Survival", "timeFrame": "1 year"}, {"measure": "ORR", "description": "Objective Response Rate", "timeFrame": "3 months"}, {"measure": "DCR", "description": "Disease Control Rate", "timeFrame": "3 months"}, {"measure": "iORR", "description": "intracranial objective response rate", "timeFrame": "3 months"}, {"measure": "iPFS", "description": "intracranial progression-free survival", "timeFrame": "3 months"}, {"measure": "SRS rate", "description": "the rate of SRS after anlotinib treatment", "timeFrame": "1 month"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n1. Patients voluntarily participate in this study, signed informed consent.\n2. Patients pathologically diagnosed as non-small cell lung cancer, with brain metastases and measurable lesions;\n3. Patients aged between 18 -80 years; with expected survival time\\>3 months.\n4. Patients with no more than 5 brain metastases\n5. Patients with normal organ function within 7 days prior to treatment, the following criteria are met:\n\n   a) blood routine examination criteria : i) hemoglobin (HB) ≥90g/L; ii) absolute neutrophil count (ANC) ≥1.5×10e9/L; iii) platelet (PLT) ≥80×10e9/L; b) biochemical tests meet the following criteria: i) total bilirubin (TBIL) ≤1.5 times of upper limit of normal (ULN); ii) alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 ULN, if liver metastasis occurred, ALT and AST ≤5 ULN; iii) serum creatinine (Cr) ≤1.5 ULN or creatinine clearance (CCr) ≥60mL/min;\n6. Female patients should agree to use contraceptives during and within 6 months after the study.\n\nExclusion Criteria:\n\n1. Patients who had previously used antiangiogenic agents within 1 month;\n2. Patients with small cell lung cancer (including small cell carcinoma and non-small cell carcinoma mixed lung cancer);\n3. Patient with lung squamous cell carcinoma that involved pulmonary hilar, or non-small cell lung cancer with hemoptysis;\n4. Patients with cerebral infarction and cerebral hemorrhage;\n5. Patients without perilesional edema；\n6. Patients with more than grade 2 (NCI-CTCAE v4.0) acute toxicity reaction due to any previous treatment.\n7. Patients with factors that affect oral medication (such as cannot swallow, chronic diarrhea and intestinal obstruction, etc.);\n8. Patients with visceral dissemination or severe symptoms, which could cause death in short term;\n9. Patients with any other severe and/or uncontrolled disease;\n10. Patients who received a surgery, a biopsy or a significant traumatic injury within 1 month;\n11. Patients with any signs or medical history of bleeding, unhealed wounds, ulcers or fractures, regardless of the severity;\n12. Patients underwent artery or venous thrombotic events within 2 months, such as deep vein thrombosis and pulmonary embolism;\n13. Patients with a history of psychotropic medicine abuse and cannot quit or have mental disorders;\n14. Patients with disease which will severely endanger their security and could not complete this study, according to the judgement of researchers；\n15. Patients who still can't tolerate SRS after anlotinib treatment, even after adding mannitol, and have to receive steroid treatment.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "80 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"centralContacts": [{"name": "Hongqing Zhuang, doctor", "role": "CONTACT", "phone": "13051776232", "email": "hongqingzhuang@163.com"}, {"name": "Yuxia Wang, doctor", "role": "CONTACT", "phone": "15001292991", "email": "lily31415926@126.com"}], "overallOfficials": [{"name": "Hongqing Zhuang, doctor", "affiliation": "Peking University Third Hospital", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Department of Radiation Oncology Cancer Center, Peking University Third Hospital 49# North Garden Rd.,Haidian Dist.", "status": "RECRUITING", "city": "Beijing", "state": "Beijing Municipality", "zip": "100191", "country": "China", "contacts": [{"name": "Hongqing Zhuang, Doctor", "role": "CONTACT", "phone": "13051776232", "email": "hongqingzhuang@163.com"}, {"name": "Yuxia Wang, Doctor", "role": "CONTACT", "phone": "15001292991", "email": "lily31415926@126.com"}, {"name": "Enmin Wang", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Yongchun Song", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Xin Wang", "role": "SUB_INVESTIGATOR"}, {"name": "Yun Guan", "role": "SUB_INVESTIGATOR"}], "geoPoint": {"lat": 39.9075, "lon": 116.39723}}]}, "referencesModule": {"references": [{"pmid": "33294918", "type": "DERIVED", "citation": "Zhuang H, Wang Y, Cheng C, Shi S. The efficacy of anlotinib instead of glucocorticoids for edema induced by brain metastases in NSCLC patients with anti-PD1/PDL-1 immunotherapy. Neuro Oncol. 2021 Jan 30;23(1):169-171. doi: 10.1093/neuonc/noaa236. No abstract available."}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-09-19"}, "interventionBrowseModule": {"meshes": [{"id": "C000625192", "term": "anlotinib"}, {"id": "D020533", "term": "Angiogenesis Inhibitors"}, {"id": "D016634", "term": "Radiosurgery"}], "ancestors": [{"id": "D043924", "term": "Angiogenesis Modulating Agents"}, {"id": "D006133", "term": "Growth Substances"}, {"id": "D045505", "term": "Physiological Effects of Drugs"}, {"id": "D020228", "term": "Pharmacologic Actions"}, {"id": "D020164", "term": "Chemical Actions and Uses"}, {"id": "D006131", "term": "Growth Inhibitors"}, {"id": "D000970", "term": "Antineoplastic Agents"}, {"id": "D045506", "term": "Therapeutic Uses"}, {"id": "D011878", "term": "Radiotherapy"}, {"id": "D013812", "term": "Therapeutics"}, {"id": "D013238", "term": "Stereotaxic Techniques"}, {"id": "D019635", "term": "Neurosurgical Procedures"}, {"id": "D013514", "term": "Surgical Procedures, Operative"}, {"id": "D008919", "term": "Investigative Techniques"}]}}, "hasResults": false}
{"protocolSection": {"identificationModule": {"nctId": "NCT04106492", "orgStudyIdInfo": {"id": "SQ3370-001"}, "secondaryIdInfos": [{"id": "2020-0185", "type": "OTHER", "domain": "MD Anderson Cancer Center"}], "organization": {"fullName": "Shasqi, Inc.", "class": "INDUSTRY"}, "briefTitle": "Phase 1/2a Study of SQ3370 in Patients With Advanced Solid Tumors", "officialTitle": "A Multicenter Phase 1/2a, Open-Label Study of SQ3370 in Patients With Advanced Solid Tumors"}, "statusModule": {"statusVerifiedDate": "2023-02", "overallStatus": "RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2020-08-01", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2024-08-07", "type": "ESTIMATED"}, "completionDateStruct": {"date": "2026-07-09", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2019-09-25", "studyFirstSubmitQcDate": "2019-09-25", "studyFirstPostDateStruct": {"date": "2019-09-27", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2023-02-08", "lastUpdatePostDateStruct": {"date": "2023-02-09", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Shasqi, Inc.", "class": "INDUSTRY"}}, "oversightModule": {"isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "The purpose of this study is to evaluate the safety, tolerability, and preliminary activity of SQ3370 in patients with advanced solid tumors."}, "conditionsModule": {"conditions": ["Cancer"], "keywords": ["Sarcoma", "Cancer", "Tumor", "Soft Tissue Sarcoma", "Solid Tumor", "Doxorubicin", "Intratumoral", "Anthracycline", "Phase 1", "Ovarian Cancer", "Precision Oncology", "Precision Chemotherapy", "Local Cancer Therapy", "Targeted Cancer Therapy", "Uterine Cancer", "Head and Neck Cancer", "Lung Cancer"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE1", "PHASE2"], "designInfo": {"allocation": "NON_RANDOMIZED", "interventionModel": "PARALLEL", "interventionModelDescription": "Phase 1 dose escalation part of the study was done sequentially. The Phase 2 part of the study will be done in parallel between the four groups.", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 145, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "Dose Escalation Cohort (10 mL SQL70)", "type": "EXPERIMENTAL", "description": "Participants will receive 10 mL of SQL70 biopolymer injected intratumorally on Day 1 of each 21-day cycle into a single lesion and then receive escalating doses of SQP33 protodrug administered IV from Day 1 through Day 5 (5 doses) of each 21-day cycle.", "interventionNames": ["Drug: SQ3370"]}, {"label": "Dose Escalation Cohort (20 mL SQL70)", "type": "EXPERIMENTAL", "description": "Participants will receive 20 mL of SQL70 biopolymer injected intratumorally on Day 1 of each 21-day cycle into a single lesion and then receive escalating doses of SQP33 protodrug administered IV from Day 1 through Day 5 (5 doses) of each 21-day cycle.", "interventionNames": ["Drug: SQ3370"]}, {"label": "Cohort A", "type": "EXPERIMENTAL", "description": "Participants will receive SQL70 biopolymer injected intratumorally on Day 1 of each 21-day cycle into a single lesion as determined in Dose Escalation. Then will receive a lower dose than RP2D of SQP33 protodrug administered IV from Day 1 through Day 5 (5 doses) of each 21-day cycle.", "interventionNames": ["Drug: SQ3370"]}, {"label": "Phase 2a Expansion Group 1 (Extremity STS)", "type": "EXPERIMENTAL", "description": "Participants with soft tissue sarcomas of the extremity AJCC Stage III OR IV (\\>5 cm injectable tumors locally advanced and or metastatic, not amendable to primary surgical intervention and who are anthracycline naïve.", "interventionNames": ["Drug: SQ3370"]}, {"label": "Phase 2a Expansion Group 2 (Unresectable STS)", "type": "EXPERIMENTAL", "description": "Locally advanced, unresectable or metastatic, soft tissue sarcomas who are anthracycline naïve.", "interventionNames": ["Drug: SQ3370"]}, {"label": "Phase 2a Expansion Group 3a (Head and Neck)", "type": "EXPERIMENTAL", "description": "Participants with histologically or cytologically confirmed relapsed or metastatic squamous-cell carcinoma of the head and neck, who have exhausted curative intent therapies or patients with distant metastases who may have received one or less chemotherapy regimen.", "interventionNames": ["Drug: SQ3370"]}], "interventions": [{"type": "DRUG", "name": "SQ3370", "description": "SQ3370 consists of 2 components: SQL70, a protodrug-activating biopolymer, and SQP33, a protodrug of Doxorubicin", "armGroupLabels": ["Cohort A", "Dose Escalation Cohort (10 mL SQL70)", "Dose Escalation Cohort (20 mL SQL70)", "Phase 2a Expansion Group 1 (Extremity STS)", "Phase 2a Expansion Group 2 (Unresectable STS)", "Phase 2a Expansion Group 3a (Head and Neck)"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Phase 1 Cohorts", "description": "To determine the Maximum Tolerated Dose, if possible, and/or Recommended Phase 2 Dose of SQ3370", "timeFrame": "From start of treatment to approximately 12 weeks"}, {"measure": "Phase 2a Expansion Groups", "description": "To evaluate safety. Defined as type, frequency, severity, timing of onset, duration, and relationship to study drugs of any treatment-emergent adverse events (TEAEs); laboratory abnormalities; vital sign abnormalities; adverse electrocardiogram (ECG) or, ECH/MUGA findings; SAEs; or AEs leading to interruption, modification, or discontinuation of study treatment", "timeFrame": "Up to 2 years"}], "secondaryOutcomes": [{"measure": "Phase 1: Pharmacokinetics (PK)", "description": "To determine Maximum Plasma concentration (Cmax) for SQP33 protodrug and active Dox following SQ3370 treatment", "timeFrame": "From start of treatment to approximately 12 weeks"}, {"measure": "Phase 1: Objective Response Rate (ORR)", "description": "Defined as achievement of complete response (CR) or partial response (PR) by RECIST v1.1", "timeFrame": "Up to 2 years"}, {"measure": "Phase 1: Duration of Response (DOR)", "description": "Defined as the interval from the first documentation of objective response to the earlier of the first documentation of disease progression or death from any cause", "timeFrame": "Up to 2 years"}, {"measure": "Phase 2a: Objective Response Rate (ORR)", "description": "Defined as achievement of complete response (CR) or partial response (PR) by RECIST v1.1", "timeFrame": "Up to 2 years"}, {"measure": "Phase 2a: Duration of Response (DOR)", "description": "Defined as the interval from the first documentation of objective response to the earlier of the first documentation of disease progression or death from any cause", "timeFrame": "Up to 2 years"}, {"measure": "Phase 2a: Overall Survival", "description": "Defined as the time between the date of enrollment to the date of death from any cause.", "timeFrame": "Up to 2 years"}, {"measure": "Phase 2a: Pharmacokinetics", "description": "Determine plasma concentration and PK parameters for SQP33 protodrug and active Dox following SQ3370 treatment", "timeFrame": "From start of treatment to approximately 12 weeks"}], "otherOutcomes": [{"measure": "Evaluate level of SQP33 in tumor", "description": "To determine the level of SQP33 protodrug and active Doxorubicin in tumor tissue", "timeFrame": "From start of treatment to approximately 12 weeks"}, {"measure": "Evaluate Pharmacodynamics (PD)", "description": "To assess immune response (changes in immune biomarkers) as assessed by PBMCs", "timeFrame": "From start of treatment to approximately 12 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Phase 1: Inclusion Criteria:\n\n1. Diagnosis of advanced soft tissue sarcoma or other solid tumors\n2. Adequate hematologic, hepatic, renal, and coagulation function\n3. ECOG performance status score 0-1\n4. Tumor is the type where published clinical data would suggest that anthracyclines have cytotoxic activity\n5. Injectable tumor present\n\nPhase 1: Exclusion Criteria:\n\n1. Prior exposure to 300 mg/m\\^2 of Dox HCl or DOXIL / CAELYX ® or 600 mg/m\\^2 of Epirubicin HCl\n2. Congestive heart failure (CHF), severe myocardial insufficiency, or cardiac arrhythmia\n3. Any of the following within 28 days prior to Cycle 1 Day 1:\n\n   * Major surgery, as defined by the Investigator\n   * Radiotherapy\n   * Chemotherapy, immunotherapy and/or anticancer therapy (except for small molecule kinase inhibitors, which are 6 elimination half-lives)\n4. Trastuzumab or trastuzumab emtansine dosed within 7 months prior to Cycle 1 Day 1.\n5. Any transfusion within 14 days prior to Cycle 1 Day 1.\n6. Pregnant or breast-feeding women.\n7. Known active CNS metastases and/or carcinomatous meningitis or symptomatic brain metastasis. Participants with previously treated brain metastases may participate provided they are radiologically stable\n8. History of allergic reactions attributed to Dox or other anthracyclines, NaHA, hyaluronic acid, or gram-positive bacterial proteins\n9. History or evidence of clinically unstable/uncontrolled disorder, condition, or disease\n\nPhase 2a Expansion Group 1 (Extremity STS): Inclusion\n\n1. Patients with unresectable soft tissue sarcomas of the extremity AJCC Stage III OR select IV (=\\>5 cm injectable tumors) locally advanced and or metastatic, not amendable to primary surgical intervention according to the consensus of a multidisciplinary treatment team, determined prior to screening.\n2. High grade STS, Grade 2/3, with an assessable/injectable lesion of at least diameter ≥5 cm by RECIST 1.1 criteria\n3. No prior chemotherapy for STS, or radiation to affected limb\n\nPhase 2a Expansion Group 1 (Extremity STS): Exclusion\n\n1. Uncontrolled pain related to tumor\n2. Open wounds or tissue necrosis related to tumor mass\n3. Compartment syndrome or impending compartment syndrome\n\nPhase 2a Expansion Group 2 (Unresectable STS): Inclusion\n\n1. Locally advanced or metastatic, unresectable, soft-tissue sarcoma of intermediate or high grade with measurable disease.\n2. Life expectancy \\>12 weeks (about 3 month)\n\nPhase 2a Expansion Group 2 (Unresectable STS): Exclusion\n\n1. Prior exposure to anthracyclines\n2. Treatment naive extremity tumors\n\nPhase 2a Expansion Group 3a (Head and Neck): Inclusion\n\n1. Patients with histologically or cytologically confirmed squamous-cell carcinoma of the head and neck (HNSCC) who meet any of the following a) confirmed relapsed HNSCC or b) metastatic at initial presentation HNSCC\n2. Patients who may have received two or less systemic regimens (therapies include chemotherapy and/or immunotherapy)\n\nPhase 2a Expansion Group 3a (Head and Neck): Exclusion\n\n1. Airway obstruction by tumor mass that requires clinical intervention\n2. Prior treatment with anthracyclines", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"centralContacts": [{"name": "Shasqi Clinical Operations", "role": "CONTACT", "phone": "415-800-1376", "email": "clinicalstudies@shasqi.com"}], "overallOfficials": [{"name": "Jim Williams, MD", "affiliation": "Shasqi, Inc.", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "City of Hope", "status": "RECRUITING", "city": "Duarte", "state": "California", "zip": "91010", "country": "United States", "contacts": [{"name": "Principal Investigator", "role": "CONTACT", "phone": "415-800-1376", "email": "clinicalstudies@shasqi.com"}], "geoPoint": {"lat": 34.13945, "lon": -117.97729}}, {"facility": "Stanford Cancer Center", "status": "RECRUITING", "city": "Palo Alto", "state": "California", "zip": "94304", "country": "United States", "contacts": [{"name": "Principal Investigator", "role": "CONTACT", "phone": "415-800-1376", "email": "clinicalstudies@shasqi.com"}], "geoPoint": {"lat": 37.44188, "lon": -122.14302}}, {"facility": "Sarcoma Oncology Center", "status": "RECRUITING", "city": "Santa Monica", "state": "California", "zip": "90403", "country": "United States", "contacts": [{"name": "Principal Investigator", "role": "CONTACT", "phone": "415-800-1376", "email": "clinicalstudies@shasqi.com"}], "geoPoint": {"lat": 34.01949, "lon": -118.49138}}, {"facility": "Washington University in St. Louis", "status": "RECRUITING", "city": "St Louis", "state": "Missouri", "zip": "63110", "country": "United States", "contacts": [{"name": "Principal Investigator", "role": "CONTACT", "phone": "415-800-1376", "email": "clinicalstudies@shasqi.com"}], "geoPoint": {"lat": 38.62727, "lon": -90.19789}}, {"facility": "Oregon Health & Science University", "status": "RECRUITING", "city": "Portland", "state": "Oregon", "zip": "97239", "country": "United States", "contacts": [{"name": "Principal Investigator", "role": "CONTACT", "phone": "415-800-1376", "email": "clinicalstudies@shasqi.com"}], "geoPoint": {"lat": 45.52345, "lon": -122.67621}}, {"facility": "MD Anderson Cancer Center", "status": "RECRUITING", "city": "Houston", "state": "Texas", "zip": "77030", "country": "United States", "contacts": [{"name": "Principal Investigator", "role": "CONTACT", "phone": "415-800-1376", "email": "clinicalstudies@shasqi.com"}], "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"facility": "University of Washington", "status": "RECRUITING", "city": "Seattle", "state": "Washington", "zip": "98195", "country": "United States", "contacts": [{"name": "Principal Investigator", "role": "CONTACT", "phone": "415-800-1376", "email": "clinicalstudies@shasqi.com"}], "geoPoint": {"lat": 47.60621, "lon": -122.33207}}, {"facility": "Chris O'Brien Lifehouse", "status": "RECRUITING", "city": "Camperdown", "state": "New South Wales", "zip": "2050", "country": "Australia", "contacts": [{"name": "Principal Investigator", "role": "CONTACT", "phone": "+1 415-800-1376", "email": "clinicalstudies@shasqi.com"}], "geoPoint": {"lat": -33.88965, "lon": 151.17642}}, {"facility": "Royal North Shore Hospital", "status": "RECRUITING", "city": "Sydney", "state": "New South Wales", "zip": "2065", "country": "Australia", "contacts": [{"name": "Principal Investigator", "role": "CONTACT", "phone": "+1 415-800-1376", "email": "clinicalstudies@shasqi.com"}], "geoPoint": {"lat": -33.86785, "lon": 151.20732}}, {"facility": "Cancer Research Institute", "status": "RECRUITING", "city": "Adelaide", "state": "South Australia", "zip": "5000", "country": "Australia", "contacts": [{"name": "Principal Investigator", "role": "CONTACT", "phone": "+1 415-800-1376", "email": "clinicalstudies@shasqi.com"}], "geoPoint": {"lat": -34.92866, "lon": 138.59863}}]}, "referencesModule": {"references": [{"pmid": "40522144", "type": "DERIVED", "citation": "Srinivasan S, Yee NA, Aleckovic M, Zakharian M, Mahmoodi A, Wagner S, Nguyen TH, Chawla SP, Guminski AD, Mejia Oneto JM. Development of a First-in-Class Click Chemistry-Based Cancer Therapeutic, from Preclinical Evaluation to a First-in-Human Dose Escalation Clinical Trial. Clin Cancer Res. 2025 Sep 2;31(17):3662-3677. doi: 10.1158/1078-0432.CCR-24-2539."}, {"pmid": "37034617", "type": "DERIVED", "citation": "Srinivasan S, Yee NA, Zakharian M, Aleckovic M, Mahmoodi A, Nguyen TH, Mejia Oneto JM. SQ3370, the first clinical click chemistry-activated cancer therapeutic, shows safety in humans and translatability across species. bioRxiv [Preprint]. 2023 Mar 29:2023.03.28.534654. doi: 10.1101/2023.03.28.534654."}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-09-19", "submissionTracking": {"estimatedResultsFirstSubmitDate": "2025-01-23", "submissionInfos": [{"releaseDate": "2025-01-23", "resetDate": "2025-02-12", "mcpReleaseN": 14}, {"releaseDate": "2025-03-21", "resetDate": "2025-04-09", "mcpReleaseN": 15}, {"releaseDate": "2025-06-23", "resetDate": "2025-07-10", "mcpReleaseN": 16}, {"releaseDate": "2025-07-16", "resetDate": "2025-07-16", "mcpReleaseN": 17}]}}, "conditionBrowseModule": {"meshes": [{"id": "D009369", "term": "Neoplasms"}, {"id": "D012509", "term": "Sarcoma"}, {"id": "D010051", "term": "Ovarian Neoplasms"}, {"id": "D014594", "term": "Uterine Neoplasms"}, {"id": "D006258", "term": "Head and Neck Neoplasms"}, {"id": "D008175", "term": "Lung Neoplasms"}], "ancestors": [{"id": "D018204", "term": "Neoplasms, Connective and Soft Tissue"}, {"id": "D009370", "term": "Neoplasms by Histologic Type"}, {"id": "D004701", "term": "Endocrine Gland Neoplasms"}, {"id": "D009371", "term": "Neoplasms by Site"}, {"id": "D010049", "term": "Ovarian Diseases"}, {"id": "D000291", "term": "Adnexal Diseases"}, {"id": "D005831", "term": "Genital Diseases, Female"}, {"id": "D052776", "term": "Female Urogenital Diseases"}, {"id": "D005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D005833", "term": "Genital Neoplasms, Female"}, {"id": "D014565", "term": "Urogenital Neoplasms"}, {"id": "D000091662", "term": "Genital Diseases"}, {"id": "D004700", "term": "Endocrine System Diseases"}, {"id": "D006058", "term": "Gonadal Disorders"}, {"id": "D014591", "term": "Uterine Diseases"}, {"id": "D012142", "term": "Respiratory Tract Neoplasms"}, {"id": "D013899", "term": "Thoracic Neoplasms"}, {"id": "D008171", "term": "Lung Diseases"}, {"id": "D012140", "term": "Respiratory Tract Diseases"}]}}, "hasResults": false}
